(NASDAQ: INSM) Insmed's forecast annual revenue growth rate of 73.65% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Insmed's revenue in 2025 is $363,707,000.On average, 5 Wall Street analysts forecast INSM's revenue for 2025 to be $83,936,638,569, with the lowest INSM revenue forecast at $81,885,915,934, and the highest INSM revenue forecast at $85,429,883,207. On average, 5 Wall Street analysts forecast INSM's revenue for 2026 to be $183,443,927,221, with the lowest INSM revenue forecast at $159,156,348,442, and the highest INSM revenue forecast at $222,086,202,450.
In 2027, INSM is forecast to generate $360,144,723,658 in revenue, with the lowest revenue forecast at $319,684,671,957 and the highest revenue forecast at $421,728,485,500.